Buda Juice Targets NYSE Listing with 'UltraFresh' IPO

Ticker: BUDA · Form: S-1/A · Filed: Dec 12, 2025 · CIK: 2079720

Sentiment: mixed

Topics: IPO, Beverage Industry, Cold-Pressed Juice, Emerging Growth Company, NYSE Listing, Food & Beverage, Consumer Staples

Related Tickers: BUDA

TL;DR

**Buda Juice is a speculative bet on 'UltraFresh' juice disrupting the market, but the IPO is a hard pass until NYSE listing is confirmed.**

AI Summary

Buda Juice, Inc. is launching its initial public offering (IPO) of 2,666,667 shares of common stock, with an estimated offering price between $7.50 and $9.00 per share. The company, which will convert from Buda Juice, LLC to a Delaware corporation prior to the offering, specializes in 'UltraFresh' cold-crafted citrus-based juices that are never heat-treated or HPP-processed. Buda Juice aims to redefine the refrigerated juice category by focusing on clean label simplicity and high-tech automation to deliver consistently safe, fresh products at scale. The company has applied to list its common stock on the NYSE under the symbol 'BUDA', with the IPO contingent upon successful listing. Key risks include the high degree of investment risk, as highlighted on page 10, and the uncertainty of NYSE listing approval. The strategic outlook involves expanding the UltraFresh juice category across multiple channels and geographies, leveraging long-term farmer relationships and an SQF-certified production plant.

Why It Matters

Buda Juice's IPO could disrupt the $20 billion+ refrigerated juice market by introducing a new 'UltraFresh' category, challenging established players who rely on pasteurization or HPP. For investors, this represents a high-risk, high-reward opportunity in a segment ripe for innovation, but the contingency on NYSE listing adds uncertainty. Employees and local farmers, particularly those in Texas, stand to benefit from the company's growth and commitment to local sourcing. Customers could gain access to genuinely fresh, nutrient-rich juice alternatives, potentially shifting consumer preferences away from processed options and intensifying competition among beverage companies.

Risk Assessment

Risk Level: high — The S-1/A filing explicitly states, 'Investing in our Common Stock involves a high degree of risk' on page 10. Furthermore, the offering is 'contingent upon the successful listing of our Common Stock on NYSE,' and 'No assurance can be given that our application will be approved,' indicating significant market and regulatory uncertainty.

Analyst Insight

Investors should monitor the outcome of Buda Juice's NYSE listing application before considering an investment. If approved, conduct thorough due diligence on the company's financials and competitive landscape, as the 'high degree of risk' warrants caution.

Financial Highlights

revenue
$11.2 million
revenue Growth
+100.0%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$11.2 million+100.0%

Key Numbers

Key Players & Entities

FAQ

What is Buda Juice's core business model?

Buda Juice is pioneering the 'UltraFresh' juice category, offering cold-crafted citrus-based drinks that are never heat-treated or HPP-processed. They focus on clean label simplicity and high-tech automation to deliver safe, fresh products at scale, primarily through established retailers.

What are the key risks associated with investing in Buda Juice, Inc.?

Investing in Buda Juice, Inc. involves a high degree of risk, as stated in the prospectus. A primary risk is that the IPO is contingent upon successful listing on the New York Stock Exchange (NYSE), and there is no assurance that the application will be approved.

How many shares is Buda Juice offering in its IPO and at what price range?

Buda Juice, Inc. is offering 2,666,667 shares of common stock in its initial public offering. The estimated offering price per share is between $7.50 and $9.00.

Who is the CEO of Buda Juice, Inc.?

Horatio Lonsdale-Hands is the Co-Founder and Chief Executive Officer of Buda Juice, Inc. He also authored the letter to prospective investors included in the S-1/A filing.

What is the significance of Buda Juice being an 'emerging growth company'?

As an 'emerging growth company' under federal securities laws, Buda Juice has elected to comply with certain reduced public company reporting requirements. This can impact the amount and type of information available to investors compared to larger, more established companies.

What is the 'Conversion' mentioned in the Buda Juice S-1/A filing?

The 'Conversion' refers to Buda Juice, LLC's plan to undertake a statutory conversion into a Delaware corporation named Buda Juice, Inc. immediately before the closing of the IPO. This legal restructuring is necessary for the company to go public as a corporation.

Where does Buda Juice source its produce?

Buda Juice leverages long-term relationships with local farmers to source only the highest-quality produce year-round. This commitment to local sourcing is a key part of their 'UltraFresh' strategy.

What is Buda Juice's strategy for growth?

Buda Juice's growth strategy involves expanding the refrigerated juice category itself by helping retailers evolve to the next generation of freshness. They aim for scalable growth through their Buda Fresh and private-brand offerings across multiple channels, geographies, and formats.

What is the underwriter's over-allotment option for Buda Juice's IPO?

The Company has granted a 45-day option to the underwriter to purchase up to an additional 400,000 shares of Common Stock. This option is solely to cover over-allotments, if any, during the IPO process.

What is Buda Juice's stance on traditional juice processing methods?

Buda Juice criticizes traditional methods like pasteurization, HPP, and UV treatment, stating they prolong shelf life but sacrifice essential nutrients and genuine taste. They explicitly state their 'UltraFresh' juices are 'never heat-treated, never HPP-processed and always cold.'

Risk Factors

Industry Context

Buda Juice operates in the refrigerated juice and wellness beverage market, a segment characterized by increasing consumer demand for healthier, fresher, and minimally processed options. The industry faces competition from both established juice brands employing traditional pasteurization or HPP, and from emerging players focusing on clean labels and unique formulations. Key trends include the growth of functional beverages, plant-based options, and a demand for transparency in sourcing and production methods.

Regulatory Implications

The company's reliance on a continuous cold chain (35°F) introduces significant operational and regulatory risks related to food safety and spoilage. Maintaining compliance with food safety regulations, particularly as the company scales and expands geographically, will be critical. The NYSE listing itself is subject to regulatory approval, posing a direct risk to the consummation of the IPO.

What Investors Should Do

  1. Review the 'High Degree of Investment Risk' section (Page 10) thoroughly.
  2. Assess the company's ability to maintain cold chain integrity at scale.
  3. Evaluate the competitive landscape and Buda Juice's differentiation strategy.
  4. Monitor NYSE listing approval status.

Key Dates

Glossary

UltraFresh TM
Buda Juice's proprietary cold-crafted juice category that is never heat-treated or HPP-processed, maintaining a continuous 35°F temperature from fruit to shelf. (This is the core differentiator for Buda Juice's products, emphasizing freshness and quality compared to traditional juices.)
Cold Chain Platform
A system that maintains a continuous low-temperature environment (35°F) throughout the product's journey from production to the retail shelf. (Essential for Buda Juice's ability to deliver 'UltraFresh' products with an 8-12 day shelf life while ensuring safety and quality.)
HPP-processed
High-Pressure Processing, a method used to preserve food and beverages by applying high pressure, often used as an alternative to heat pasteurization. (Buda Juice explicitly states its products are *not* HPP-processed, highlighting a key distinction from many other 'fresh' juices on the market.)
CAGR
Compound Annual Growth Rate, a measure of the average annual growth of an investment over a specified period of time longer than one year. (Used to quantify Buda Juice's revenue growth, showing a 41.8% CAGR from $5.6 million in 2022 to $11.2 million in 2024.)
SQF-certified
Safe Quality Food, a rigorous food safety and quality certification program recognized by retailers and food service providers worldwide. (Indicates that Buda Juice's production plant meets high standards for food safety, which is crucial for consumer confidence and retailer partnerships.)

Year-Over-Year Comparison

This S-1/A filing provides updated financial information showing significant revenue growth, with revenue increasing from $5.6 million in 2022 to $11.2 million in 2024, representing a 100% increase over the period or a 41.8% CAGR. While specific net income and margin figures for the most recent period are not detailed in this excerpt, the substantial revenue growth suggests positive operational momentum. New risks related to the NYSE listing contingency and the operational complexities of maintaining the 'UltraFresh' cold chain at scale have been highlighted.

Filing Stats: 4,304 words · 17 min read · ~14 pages · Grade level 14.8 · Accepted 2025-12-12 17:28:12

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 32 DIVIDEND POLICY 33 CAPITALIZATION 34

DILUTION

DILUTION 35 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 46 MANAGEMENT 55 EXECUTIVE AND DIRECTOR COMPENSATION 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 64 PRINCIPAL STOCKHOLDERS 65

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 66 SHARES ELIGIBLE FOR FUTURE SALE 69 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 70

UNDERWRITING

UNDERWRITING 74 LEGAL MATTERS 77 EXPERTS 77 WHERE YOU CAN FIND MORE INFORMATION 77 INDEX TO FINANCIAL STATEMENTS F-1 i Neither we nor the underwriter have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriter have done anything that would permit this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the Offering of the shares of Common Stock and the distribution of this prospectus outside the United States. This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” ii ABOUT THIS PROSPECTUS Except where the context otherwise requires or where otherwise indicated throughout this registration statement, the terms “Buda Juice, LLC,” “Buda Juice, Inc.,” “Buda Juice,&rd

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. If our listing application is not approved by the New York Stock Exchange (“NYSE”), we will not be able to consummate the Offering. Overview Buda Juice is pioneering the UltraFresh TM juice category through our end-to-end cold chain platform that delivers always cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. We bridge the gap between shelf-stable products and operationally challenging in-store juicing, enabling any retailer to offer truly fresh and safe juice without infrastructure investment or operational complexity. Our breakthrough lies in solving the industry’s fundamental challenge: delivering UltraFresh TM quality on a retail scale. We maintain continuous 35°F temperature control from fruit to shelf, delivering products with 8-12 day shelf life - long enough for retail distribution yet fresh enough to preserve authentic taste. This eliminates the traditional tradeoffs between shelf life, flavor, and nutrient quality in the industry. We have validated our model through strong financial performance, growing revenue from $5.6 million in 2022 to $11.2 million in 2024, representing a 41.8% CAGR. Currently operating from our Dallas plant, we are executing a disciplined geographic expansion strategy with planned facilities in South Carolina (2026) and Arizona/Nevada (2027), enabling us to serve a large percentage of the U.S. population. Our Products Our product portfolio consists of fresh citrus juice, fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using our cold chain process: Products (1) Buda Juice (Organic) Wellness shots in 2 oz format Available in 2-pack and 6-pack glass bottle configurations (2) Buda Fresh – Value-Forward Offering (Non-Organic) 12 oz Lime Juice, 16 oz

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing